Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
novartis
10 tablet Per Strip
Imatinib
Keep in cold place
Delivering To:
Overview
Glivec 400mg tablet is a prescription-based anticancer medicine, used for the treatment of several types of cancers, including gastrointestinal stromal tumors and blood cancers (chronic myeloid leukemia and acute lymphocytic leukemia). It mainly functions by stopping the spread of cancer cells by targeting the specific protein associated with the multiplication of cancer cells. This helps slow or even stop the growth of the cancer, make the patients feel better. Glivec 400mg tablet is also used for the treatment of a skin tumor called dermatofibrosarcoma protuberans and aggressive systemic mastocytosis, a type of bone marrow condition.
Blood Cancer
Blood cancer (Chronic myeloid leukaemia)
Gastrointestinal stromal tumour
Treatment of Cancer
The human body reacts differently to the Glivec 400mg tablet. Response or undesired symptoms vary from individual to individual. Usually, they disappear with time as the body adjusts to the medicine; these side effects don't need special medical attention. Whereas if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately. Some of the common side effects of the Glivec 400mg tablet are mentioned below: Diarrhea
Vomiting
Nausea
Loss of appetite
Dizziness
Extreme fatigue
Blurred vision
Irregular heart rate
Chest pain
Muscle cramps
Pink eye
Redness and rashes, Swelling of joints
Trouble sleeping
Hair loss
Shortness of breath
Yellowing of eyes and skin
Pink mucous in the cough
Sudden weight loss or weight gain
Take the dose of the Glivec 400mg tablet as per your healthcare provider’s prescription. Do not stop taking the medicine suddenly, unless your doctor tells you. This medicine is given under the strict supervision of a doctor. Do not self-administer. Overdose is a very unusual state for this medicine because it is given under the supervision of a healthcare provider. Glivec 400mg tablet can be taken without food or with food. The doctor will provide emergency medical treatment. You should not break, crush, or chew the medicine; it should be swallowed as a whole.
Glivec 400mg tablet stops the growth and spread of cancer by targeting the specific protein that helps the tumour cells to grow. It is an anticancer medication. Glivec 400mg tablet is an anti-cancer medication that inhibits the proliferation of BCR-ABL tyrosine kinase, a protein enzyme. This enzyme helps cancer cells multiply and is responsible for the abnormal proliferation of cancer cells. Glivec 400mg tablet also induces apoptosis (programmed cell death) in BCR-ABL positive cells (cancer cells) and shows antineoplastic properties, stopping or slowing the spread of cancer cells.
Alcohol
unsafe
The interaction of alcohol with this drug is still unknown. It is advisable not to consume alcohol while taking the Glivec 400mg tablet. Consult your doctor for further information.
Pregnancy
consult your doctor
Glivec 400mg tablet may be considered unsafe during pregnancy. Please consult your doctor in such a condition. According to some research data, taking the Glivec 400mg tablet during pregnancy has shown harmful effects on the developing baby.
Breast Feeding
consult your doctor
Glivec 400mg tablet is probably not safe if you're breastfeeding. Kindly consult your doctor before taking the Glivec 400mg tablet while breastfeeding, as there is a chance that it may pass to the developing baby through the breast milk of the mother.
Driving
danger
It is advisable not to drive or operate heavy machinery after taking the Glivec 400mg tablet, as you may feel dizzy.
Kidney
caution
Share your medical history with your healthcare expert in case of kidney disease before taking the Glivec 400mg tablet. Patients with renal impairment must be careful while taking the Glivec 400mg tablet. They may require adjustment in the dose.
Liver
caution
Inform your doctor before starting the Glivec 400mg tablet if you have liver disease to avoid any serious side effects. Patients with hepatic impairment must be careful while taking the Glivec 400mg tablet. They may require adjustment in the dose.
It is advisable to avoid missing any doses. In case you miss a dose of Glivec tablets consult your doctor immediately.
Glivec is an anticancer tablet that is primarily used in the treatment of blood cancer.
Glivec tablets are taken orally once or twice every day as advised by the doctor.
The doctor decides for how long the treatment with Glivec will continue depending on the condition, stage, and health of the patient.
It is advisable to avoid driving and operating heavy machinery as Glivec 400mg causes dizziness as one of the side effects.
Glivec can cause harm to the fetus hence it is advisable to avoid the pregnancy or consult the doctor for the same.
Memory impairments have been reported in a few patients. Consult your doctor if you face problems with concentration, loss of memory, or are confused.
Time and dose are decided by your doctor. A Glivec 400mg tablet should be taken at the same time, usually with a meal and a large glass of water to avoid stomach problems.
No, children below 18 years of age are not advised to take the Glivec 400mg tablet as it results in severe complications.
No, it is advised to avoid taking the Glivec 400mg tablet if you have serious kidney problems. Consult the doctor before taking this medication.
If you take extra doses of the Glivec 400mg tablet, then you should immediately go to the hospital emergency room or call your healthcare provider right away.
At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.
Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.
Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.
We currently ship to:
Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!
Peng B, Dutreix C, Mehring G, Hayes MJ, Ben-Am M, Seiberling M, Pokorny R, Capdeville R, Lloyd P. (2024). Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol. 44(2):158-62.
Zhu J, Yang Y, Zhou L, Jiang M, Hou M. (2024). A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome. BMC Cancer. 10:199.
Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y. (2025). Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 279(5350):577–580.
Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. (2024). KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol. 160(5):1567–1572.
Mudan SS, Conlon KC, Woodruff JM, Lewis JJ, Brennan MF. (2025). Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Cancer. 88(1):66–74.
Demetri GD, von Mehren M, Blanke CD, Abbeele AD Van den, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. (2024). Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 347(7):472–480.
novartis
Written By
Venika Choudhary
Medical Content Writer @ Magicine Pharma
I hold an M.Sc. in Microbiology and have a strong academic foundation in microbial sciences and applied biotechnology. I began my career with extensive hands-on research at CSIR laboratories, focusing on fungal enzyme production, studying fungal diversity in various ecosystems, and developing bio-pesticides as sustainable alternatives to chemical pesticides. This work deepened my understanding of fungal biology, bioactive compounds, and their pharmaceutical and agricultural applications. Transitioning from research, I now work as a medical content writer, where I combine my scientific expertise with a passion for clear and reliable healthcare communication. I apply my research background to create patient-friendly, compliant content for pharmaceutical companies and healthcare platforms, ensuring science is both trustworthy and accessible. Specializing in clear, accurate, and engaging content, I help patients make informed decisions and support pharmaceutical companies in delivering trusted information. Whether writing product descriptions, crafting disease awareness articles, or composing drug information leaflets, I consistently meet regulatory standards and address audience needs, making my content an asset for healthcare brands.
Reviewed By
Dr. Aditya Sarin - MBBS, MD, DrNB - Consultant Medical Oncology
Dr. Aditya Sarin, MBBS, MD, DrNB, is a highly qualified medical oncologist with profound research and clinical expertise, currently working at Sir Ganga Ram Hospital, New Delhi. He is also a member of the European Society of Medical Oncology (ESMO), a non-profit European organization dedicated to eradicating cancer by promoting comprehensive cancer care and advancing medical oncology. He has been honored with several awards, including the International Cancer Foundation scholarship (ESMO congress, 2022) and Young Medical Oncologist of the Year (Times of India, 2024). He is well-known for his breakthrough in oncology. Dr. Sarin is passionate about converting complex health information into a concise and clear form that is understandable to everyone, aiming to create awareness and cancer care among people.